Fig. 6: Hippo signalling is activated acutely in patient-derived models following osimertinib treatment. | Communications Biology

Fig. 6: Hippo signalling is activated acutely in patient-derived models following osimertinib treatment.

From: Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer

Fig. 6

a Schema of patient-derived xenograft models, osimertinib response status, and assays used. b Nuclear YAP1 expression in a panel of 10 EGFR mutant lung cancer PDX models derived from patients classified as either osimertinib sensitive or resistant. Each dot indicates expression from a separate implanted mouse. The putative resistance mutation/copy number alteration is indicated above each resistant model. c (Left panel) Tumour volume measurements in EGFR mutant lung cancer PDX models CTG-2548 and LU5221 following 28 days of treatment with osimertinib in vivo; (Right panel) nuclear immunofluorescence of YAP1 and WWTR1 at timepoints t0 (pre-treatment) and t1 (28 days of treatment).

Back to article page